For the small subset of patients diagnosed with advanced lung adenocarcinoma carrying epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements, several options including the tyrosine kinase inhibitors, erlotinib and gefitinib, are now available [4]. The gene discussed is ALK; the disease is lung adenocarcinoma.